Since the early beginnings, in the 1950s, hematopoietic stem cell transplantation (HSCT)
has become an established curative treatment for an increasing number of patients with life …

Microchimerism (Mc) refers to the harboring of a small number of cells (or DNA) that
originated in a different individual. Naturally acquired Mc derives primarily from maternal …

Optimal cord blood (CB) unit selection is critical to maximize the likelihood of successful
engraftment and survival after CB transplantation (CBT). However, unit selection can be …

Common understanding suggests that the normal function of a “healthy” immune system
safe-guards and protects against the development of malignancies, whereas a genetically …

Maternal microchimerism (MMc) has been associated with development of allospecific
transplant tolerance, antitumor immunity, and cross-generational reproductive fitness, but its …

Transplantation-related mortality (TRM) is high after HLA-mismatched umbilical cord blood
(UCB) transplantation (UCBT). In utero, exposure to noninherited maternal antigen (NIMA) is …

Prevention of hepatitis B virus (HBV) transmission from infected mothers to their newborns is
critical to HBV control and eventual eradication. Mother-to-child perinatal transmission …

Unrelated umbilical cord blood transplantation (UCBT) exhibits a low risk of graft-versus-
host-disease (GvHD) and has unique potent anti-virus and anti-leukemia effects. Anti …

Graft-versus-host disease (GVHD) is a potentially life-threatening complication of allogeneic
hematopoietic cell transplantation. Many genes are presumed to be involved in GVHD, but …

Greater use of umbilical cord blood (UCB) for hematopoietic cell transplantation (HCT) is
limited by the number of cells in banked units. Ex vivo culture strategies have been …